Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Develops receptor-targeted therapeutics for the treatment of cancer.
Year Established: | 1996 |
Funding: | 26 |
Address: | West Lafayette, IN 47906 |
Telephone: | 2147483647 |
Mobile: | |
Fax: | 765.463.9271 |
Mail: | info@endocyte.com |
Company URL: | http://www.endocyte.com |
We welcome people who thrive on new challenges, value creativity, enjoy an entrepreneurial environment, and share our passion for developing new and better medicines. Our commitment to improving the lives of patients is paramount to everything we do and the guiding spirit behind our mission. Working with leading research institutions like Purdue University, we are working on developing better treatments for a wide variety of diseases. Endocyte offices are located in the Purdue Research Park in West Lafayette, Indiana, and in Indianapolis, Indiana. Our Values at Endocyte We work together. Effective TEAMWORK requires a positive attitude, mutual trust and respect, commitment to the team, and open, constructive discussion. We expect EXCELLENCE in our work and thinking. Excellence requires a commitment to high standards, continuous improvement, and constant learning. We are COMMITTED to achievement of our goals through focus, hard-work, creativity, and determination. For information about professional opportunities at Endocyte, visit the Endocyte Job Listings. |
Endocyte presents data on EC145 in treatment of ovarian cancer at the 16th annual meeting of the European Society of Gynaecologic Oncology
--October 21, 2009
Endocyte announces close of $26 million equity financing
--October 15, 2009
Endocyte announces achievement of second milestone in collaboration with Bristol-Myers Squibb
--August 26, 2009
Endocyte announces positive results from a Phase II clinical study of EC145 in patients with advanced non-small cell lung cancer (NSCLC)
--August 10, 2009
Endocyte initiates phase 1 trial of EC0489 for treatment of refractory or metastatic solid tumors
--May 05, 2009
Endocyte to present multiple abstracts at the 100th annual meeting of the american association for cancer research (AACR)
--April 17, 2009
Endocyte announces positive interim results from phase II clinical trial of EC145 in patients with advanced non-small cell lung cancer (NSCLC)
--March 24, 2009
Endocyte begins phase II clinical trial of EC145 for treatment of women with ovarian cancer
--February 19, 2009
Endocyte to Present at the BIO Investor Forum 2008
--October 13, 2008
Endocyte Receives "Indiana Companies to Watch" Award
--September 10, 2008
Endocyte Secures $15 Million Venture Debt Facility
--January 25, 2008
Endocyte Announces Achievement of Milestone in Collaboration with Bristol-Myers Squibb
--January 04, 2008
Endocyte to Present at the 26th Annual JPMorgan Healthcare Conference
--January 03, 2008
Endocyte Announces License Agreement with R&D Biopharmaceuticals for the Development of Targeted Tubulysin Chemotherapeutic Agents
--December 21, 2007
Chandra Lovejoy joins Endocyte as Director of Regulatory Affairs
--December 17, 2007
Endocyte secures $15 million in Series C-3 round of financing
--March 23, 2007
Endocyte awarded patent for vitamin-targeted imaging agent
--November 29, 2006
Purdue honors faculty entrepreneurs for life-altering inventions
--October 11, 2006
Michael A. Sherman Joins Endocyte as CFO
--October 09, 2006
Keith E. Brauer Joins the Endocyte Board of Directors
--September 12, 2006
Endocyte Signs Agreement with Bristol-Myers Squibb to Develop and Commercialize Folate-Targeted Chemotherapeutic Agents
--January 05, 2006
Blue Chip Venture Company,Clarian Health Ventures, Inc.,Sanderling Ventures,Triathlon Medical Ventures LLC,Undisclosed Firm
Ron Ellis
President & CEO
Mike Sherman
CFO